Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples